More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$105347076
EPS
-1.15
P/E ratio
--
Price to sales
0.36
Dividend yield
--
Beta
1.482036
Previous close
$0.80
Today's open
$0.78
Day's range
$0.78 - $0.83
52 week range
$0.73 - $6.20
show more
CEO
Gary S. Gillheeney
Employees
854
Headquarters
Canton, MA
Exchange
NASDAQ Capital Market
Shares outstanding
129801720
Issue type
Common Stock
Healthcare
Pharmaceuticals
Organogenesis: 3 Key Takeaways for Long-Term Investors
Organogenesis increased third quarter net product revenue 6% quarter over quarter. Management expects annual operating expense reductions of approximately $45 million.
The Motley Fool • Nov 6, 2026

Organogenesis Holdings Inc. (ORGO) Q3 2026 Earnings Call Transcript
Organogenesis Holdings Inc. ( ORGO ) Q3 2026 Earnings Call November 5, 2026 5:00 PM EST Company Participants Gary Gillheeney - President, CEO, Chair of the Board David Francisco - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG, LLC, Research Division Ravi Misra - Truist Securities, Inc., Research Division Presentation Operator Welcome, ladies and gentlemen, to the Third Quarter 2026 Earnings Conference Call for Organogenesis Holdings Inc. [Operator Instructions] Please note that this conference call is being recorded and that the recording will be available on the company's website for replay shortly. Before we begin, I would like to remind everyone that our remarks today may contain forward-looking statements that are based on the current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including the risks and uncertainties described in the company's filings with the Securities and Exchange Commission, including Item 1A, Risk Factors, of the company's most recent annual report and its subsequently filed quarterly reports.
Seeking Alpha • Nov 7, 2026

Organogenesis Q3 Earnings Call Highlights
Organogenesis NASDAQ: ORGO reported a 70% year-over-year decline in third-quarter net product revenue and lowered the upper end of its full-year revenue outlook as the skin substitute market recovered more slowly than management had anticipated.
MarketBeat • Nov 6, 2026

Organogenesis Holdings Inc. Reports Third Quarter 2026 Financial Results
CANTON, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacture, and sale of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the third quarter ended September 30, 2026.
GlobeNewsWire • Nov 5, 2026

Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026
CANTON, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports medicine markets, today announced that third quarter of fiscal year 2026 financial results will be reported after the market closes on Thursday, November 5th.
GlobeNewsWire • Oct 12, 2026

Organogenesis Announces Publication of Peer-Reviewed PREPARE Trial Results Demonstrating Clinical Benefit of PuraPly®AM for Hard-to-Heal Diabetic Foot Ulcers
CANTON, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the publication of previously released results from PREPARE1, a prospective, multicenter, randomized controlled trial (RCT) evaluating PuraPly®AM (PCMP) plus standard of care (SoC) compared to SoC alone in hard-to-heal diabetic foot ulcers (DFUs). The trial achieved its primary endpoint, and the results published in the Journal of Wound Care demonstrate statistically significant improvements in wound closure at 12 weeks among patients treated with PuraPly®AM plus SoC, providing clinical evidence supporting the use of PuraPly®AM in one of the most costly and difficult-to-treat chronic wound populations.
GlobeNewsWire • Oct 12, 2026

These beaten-down stocks could bounce back in January, if history is any guide
Tax-loss selling is likely to lead these 20 stocks to become artificially depressed in the fourth quarter — and therefore good bets to bounce back in the new year
Market Watch • Sep 21, 2026

Organogenesis Q2 Earnings Call Highlights
Organogenesis NASDAQ: ORGO reported a sharp year-over-year decline in second-quarter revenue as the skin substitute market continued to adjust to coverage and payment changes from the Centers for Medicare & Medicaid Services, while management pointed to sequential improvement in product sales and market share gains.
MarketBeat • Aug 7, 2026

Organogenesis Holdings Inc. (ORGO) Q2 2026 Earnings Call Transcript
Organogenesis Holdings Inc. (ORGO) Q2 2026 Earnings Call Transcript
Seeking Alpha • Aug 7, 2026

Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results
CANTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacture, and sale of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the second quarter ended June 30, 2026.
GlobeNewsWire • Aug 6, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Organogenesis Holdings Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.